Why the Healthcare stocks CASI Pharmaceuticals Inc (NASDAQ:CASI) Top Gainer Today? | BNinvestors

During Wednesday’s Morning trade, Shares of CASI Pharmaceuticals Inc (NASDAQ:CASI), inclined 53.87% to $1.55. The firm opened its current trade at $1.14, and as of now, it is trading at $1.56. The total volume traded for the day is 6.00M shares, as compared to its average daily volume of 40,698.00 shares. The stock is floating in a range of $1.10 $1.82. The stock holda the market capitalization of $ 50.94M, as

CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, declares that its oncology drug candidate, ENMD-2076, has received Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of hepatocellular carcinoma (HCC), counting fibrolamellar carcinoma (FLC), a rare type of HCC.

The designation provides CASI with 10 years of market exclusivity in EU after ENMD-2076 receives marketing authorization there. The product was also granted Orphan Drug designation for the treatment of HCC by US Food and Drug Administration (FDA) in 2014, which provides CASI with a 7-year market exclusivity in the country after its New Drug Application approval.

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. Its product pipeline comprises ENMD-2076, ZEVALIN, MARQIBO, CE Melphalan and 2ME2 (2-methoxyestradial). Its lead internal drug candidate is ENMD-2076 is a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ZEVALIN is indicated for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkins lymphoma.


This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.

Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.

Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.

Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.

About Travis Garlick 1791 Articles
Been writing about and trading stocks since 2013. Manage a group of micro-cap investors on Facebook with over 15,000 members. Turned $8,500 into 185k the first year I started trading stocks and haven't looked back.